Investigational drug · Phase 3
goflikicept
Also called: RPH-104, Arcerix
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Familial Mediterranean Fever, FMF, Idiopathic Recurrent Pericarditis.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
6
Any phase or sponsor naming "goflikicept"
First trial start
2020
Dec 11, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "goflikicept", any sponsor or status.
Conditions studied
As listed on its trial records.
- Familial Mediterranean Fever
- FMF
- Idiopathic Recurrent Pericarditis
- Still Disease
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "goflikicept" as an intervention, largest first.
- Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy VolunteersPivotal-lookingCompleted
R-Pharm International, LLCIndustry
NCT07206043 · 130 participants · Start Dec 3, 2024 · Primary completion Feb 27, 2025
Drug: RPH-104 80 mg; RPH-104 160 mg and 5 more · For: Healthy
Sites: Moscow, Russia
- Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial InfarctionPivotal-lookingCompleted
R-Pharm Overseas, Inc.Industry
NCT04463251 · 102 participants · Start Dec 7, 2020 · Primary completion Nov 3, 2021
Drug: RPH-104 80 mg; Placebo · For: Acute ST Segment Elevation Myocardial Infarction
Sites: Cleveland, Ohio; Charlottesville, Virginia; Richmond, Virginia · 11 sites in all
- Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's DiseasePivotal-lookingNot yet recruiting
R-Pharm International, LLCIndustry
NCT07625384 · 52 participants (planned) · Start May 18, 2026 · Primary completion Dec 14, 2027
Drug: Placebo; Goflikicept and 1 more · For: Still Disease
Sites: Izhevsk, Russia; Kazan', Russia; Korolyov, Russia · 25 sites in all
- Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean FeverPivotal-lookingNot yet recruiting
R-PharmIndustry
NCT07880886 · 18 participants (planned) · Start Dec 2026 · Primary completion May 2029
Drug: RPH-104 · For: Familial Mediterranean Fever; FMF
Sites: Moscow, Russia; Saint Petersburg, Russia · 3 sites in all
- Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent PericarditisPivotal-lookingActive, not recruiting
R-Pharm International, LLCIndustry
NCT05673902 · 17 participants · Start Dec 11, 2020 · Primary completion Jan 2026
Drug: RPH-104 · For: Idiopathic Recurrent Pericarditis
Sites: Saint Petersburg, Russia
- Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)Pivotal-lookingWithdrawn
R-Pharm International, LLCIndustry
NCT05432960 · 0 participants · Start Dec 2023 · Primary completion Aug 2025
Drug: RPH-104; Placebo · For: Adult-Onset Still's Disease; AOSD
Sites: Moscow, Russia; Saint Petersburg, Russia · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Dressler syndrome and post-cardiac injury syndrome: an autoinflammatory framework for reappraising a seventy-year-old diagnosis: a state-of-the-art review.
Sethi Y, Moinuddin A, Mahajan K, et al. · Front Immunol 2026
- Single-cell RNA profiling suggests goflikicept-mediated immune modulation in idiopathic recurrent pericarditis.
Golovkin A, Markelova E, Ignatieva EV, et al. · Inflamm Res 2026
- Updates on Pathophysiology of Pericarditis to Guide Development of Therapeutics.
Bonaventura A, Vecchié A, Mauro AG, et al. · Curr Cardiol Rep 2026
- Goflikicept and Related IL-1 Inhibitors in the Treatment of Recurrent Pericarditis.
Feldman JM, Frishman WH, Aronow WS · Cardiol Rev 2026
- Pericarditis at the crossroads: Unlocking the next wave of therapies.
Imazio M, Venturelli F, Tomat MC, et al. · Int J Cardiol Heart Vasc 2025
- Heart Failure With Preserved Ejection Fraction: How far we have Come: A Brief Report From Two Outstanding Educational Events.
Abbate A · J Cardiovasc Pharmacol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.